{
    "clinical_study": {
        "@rank": "67183", 
        "arm_group": {
            "arm_group_label": "Combivent Respima via ventilator adapter", 
            "arm_group_type": "Experimental", 
            "description": "Patients (all); previously intubated and ventilated; in need of bronchodilation with /CVT-R"
        }, 
        "brief_summary": {
            "textblock": "The general aim of this 1-day, open label, non-randomised, trial is to characterize the\n      performance of an adapter device designed to permit use of the Respimat\u00ae inhaler with\n      patients requiring mechanical ventilation."
        }, 
        "brief_title": "Ventilator Adapter for Combivent Respimat", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  All patients or their health care proxy must sign an informed consent consistent with\n             International Conference on Harmonization (ICH)-Good Clinical Practice (GCP)\n             guidelines prior to participation in the trial.\n\n          -  Male or female patients, 40 years of age or older\n\n          -  Patients must have a pre-admission/pre-ventilation diagnosis of chronic obstructive\n             pulmonary disease, and have a history of treatment with an inhaled bronchodilator.\n\n          -  Chronic Obstructive Pulmonary Disease (COPD) patients must be current or ex-smokers\n             with a smoking history of at least 10 pack years. Note that the availability of prior\n             confirmatory spirometry is desirable but not required for participation in the trial\n\n          -  Patients must have a clinically relevant and acceptable elective or semi-elective\n             indication for intubation and initiation of mechanical ventilation prior to\n             consideration for trial enrollment.\n\n        Exclusion criteria:\n\n          -  Patients with disease, respiratory or non-respiratory, that is sufficiently unstable\n             (beyond the need for intubation and routine mechanical ventilation) such that their\n             condition will, in the opinion of the investigator (i) put them at risk because of\n             participation in the study, (ii) influence the results of the study [including the\n             assessment of pharmacokinetic parameters], or (iii) cause concern regarding their\n             ability to participate in the study for its duration of one (nominal) day.\n\n          -  Patients with any of the following specific conditions:\n\n               -  A history or diagnosis or treatment of asthma within the previous 10 years\n\n               -  A current indication for \"crash\" or emergency intubation and ventilation (such\n                  as a cardio and/or respiratory arrest).\n\n               -  Any systemic or respiratory condition or degree of instability that in the\n                  judgment of the principal investigator renders the patient unlikely to safely\n                  participate in or complete the study. Investigators are encouraged to contact\n                  the trial clinical monitor or team member medicine should there be any question\n                  about the suitability of a particular patient for this study.\n\n               -  A diagnosis of thyrotoxicosis (due to the known class side effect profile of\n                  \u00df2-agonists)\n\n               -  A diagnosis of paroxysmal tachycardia (>100 beats per minute) (due to the known\n                  class side effect profile of \u00df2-agonists)\n\n               -  A myocardial infarction within the past six weeks\n\n               -  Unstable or life-threatening cardiac arrhythmia within the past six weeks\n\n               -  A diagnosis of Class III or IV heart failure  within the past six weeks\n\n               -  Renal and/or hepatic failure to an extent likely to significantly affect drug\n                  metabolism and the consequent effect on the determination of pharmacokinetic\n                  parameters as determined by the investigator.\n\n               -  Known active tuberculosis\n\n               -  Currently under treatment with chemotherapy or radiation therapy for a\n                  malignancy.\n\n               -  Clinically evident bronchiectasis\n\n          -  Patients who have taken an investigational drug within one month or six half lives\n             (whichever is greater) prior to screening. (Note that for the purpose of this trial,\n             commercially available and previously prescribed/administered Combivent Respimat\u00ae or\n             Combivent Metered Dose Inhaler (MDI) will not be precluded as \"investigational\".)\n\n          -  Patients with known hypersensitivity to \u00df-adrenergics drugs, anticholinergic drugs,\n             Benzalkonium chloride (BAC), Ethylenediaminetetraacetic acid (EDTA), or any other\n             component of the Respimat\u00ae inhalation solution delivery system\n\n          -  Pregnant or nursing women\n\n          -  Women of childbearing potential not using two effective methods of birth control (one\n             barrier and one non-barrier). Female patients will be considered to be of\n             childbearing potential unless surgically sterilized by hysterectomy or bilateral\n             tubal ligation, or post-menopausal for at least two years\n\n          -  Patients who have previously been randomised in this study or are currently\n             participating in another study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969539", 
            "org_study_id": "1012.65"
        }, 
        "intervention": {
            "arm_group_label": "Combivent Respima via ventilator adapter", 
            "description": "Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R", 
            "intervention_name": "Combivent Respimat via ventilator adapter", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Danbury", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "1012.65.00001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1012.65.00002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open Label, Non-randomised, 1-day Trial to Characterize the Performance of an Adapter Device Designed to Permit Use of the Respimat\u00ae Inhaler Device With Patients Requiring Mechanical Ventilation.", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "maximum measured concentration (Cmax) of ipratropium and albuterol", 
            "safety_issue": "No", 
            "time_frame": "6, 12 and 18 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969539"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "area under the concentration-time curve over the time interval from 0 to 6 hour (AUC 0-6) of ipratropium and albuterol", 
            "safety_issue": "No", 
            "time_frame": "6, 12 and 18 hours"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}